<article id="tolerability_CRVO" class="slide" data-ag-name="Tolerability CRVO">
  <div class="tab-title">CRVO</div>
  <h2 class="slide-title">DEMONSTRATED TOLERABILITY<sup class="footnote-link">1</sup></h2>
   <p>Of the 2728 intravitreal injections during Phase III trials, three serious ARs related to the injection procedure (endophthalmitis) occurred.<br><br>Most common serious AEs reported in â‰¥2 patients and more frequently in the EYLEA<sup class="reg">&reg;</sup>+PRN group 
   <br>vs. Sham+PRN included, cataract 2% vs. 1%, macular edema 2% vs. 1%, cystoid macular edema 1% vs. 0%.</p>
  <div class="chart-header">Most common adverse events reported more frequently with EYLEA<sup class="reg">&reg;</sup>+PRN in at least one clinical trial through Weeks 76/100<span class="asterisk">*</span></div>
  <div class="chart-img"><img src="content_EN/img/charts_t-crvo.png" /></div>
  <div class="keys"><div class="chart-key">* Combined safety data for COPERNICUS and GALILEO trials.</div></div>
</article>